Adaptive Biotechnologies Corporation
ADPT
$17.52
$0.744.38%
NASDAQ
| 03/31/2026 | 12/31/2025 | 09/30/2025 | 06/30/2025 | 03/31/2025 | |
|---|---|---|---|---|---|
| Revenue | 295.41M | 276.98M | 252.75M | 205.22M | 189.53M |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | 295.41M | 276.98M | 252.75M | 205.22M | 189.53M |
| Cost of Revenue | 166.28M | 165.13M | 166.38M | 165.38M | 167.92M |
| Gross Profit | 129.13M | 111.85M | 86.38M | 39.83M | 21.61M |
| SG&A Expenses | 174.16M | 167.27M | 162.87M | 159.25M | 156.10M |
| Depreciation & Amortization | 1.70M | 1.70M | 1.70M | 1.70M | 1.70M |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 342.13M | 334.10M | 330.94M | 326.33M | 325.71M |
| Operating Income | -46.73M | -57.12M | -78.19M | -121.11M | -136.19M |
| Income Before Tax | -49.64M | -59.46M | -79.60M | -121.24M | -141.89M |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | -49.64 | -59.46 | -79.60 | -121.24 | -141.89 |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -38.00K | -42.00K | -17.00K | 8.00K | 55.00K |
| Net Income | -49.68M | -59.50M | -79.61M | -121.23M | -141.84M |
| EBIT | -46.73M | -57.12M | -78.19M | -121.11M | -136.19M |
| EBITDA | -29.79M | -39.29M | -60.10M | -102.84M | -117.41M |
| EPS Basic | -0.32 | -0.39 | -0.53 | -0.81 | -0.96 |
| Normalized Basic EPS | -0.20 | -0.25 | -0.34 | -0.52 | -0.58 |
| EPS Diluted | -0.33 | -0.40 | -0.54 | -0.82 | -0.96 |
| Normalized Diluted EPS | -0.21 | -0.25 | -0.35 | -0.52 | -0.58 |
| Average Basic Shares Outstanding | 613.16M | 606.84M | 601.39M | 596.47M | 591.80M |
| Average Diluted Shares Outstanding | 623.89M | 617.57M | 612.12M | 596.47M | 591.80M |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |